Stopping acid-reducing pills in stable IBD
Part of Digestive system clinical trials.
This study tests whether it is safe to stop taking acid-reducing pills (PPIs) for people with inactive IBD. If you have been on a PPI for over 6 months and your IBD is stable, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years old or older.
- You have been diagnosed with inflammatory bowel disease (IBD) like Crohn's or colitis.
- You have been taking a PPI (acid-reducing medicine) regularly for at least 6 months.
- Your IBD has been stable for the past 3 months (no changes in medicine or surgery).
- You do not have serious stomach conditions like Barrett's esophagus or peptic ulcers.
- You are not taking daily NSAIDs (like ibuprofen) and do not have other serious health issues listed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether it is safe to stop taking an immunosuppressant medication in older adults (60+) with ulcerative colitis that has been in remission for a long time. By stopping the drug, they hope to reduce side effects while keeping the disease under control.
This trial tests whether people with ulcerative colitis who have been in deep remission (no signs of active disease) can safely reduce or stop their current medication. It aims to find out if careful monitoring can keep them healthy without full-dose treatment.
This study looks at whether it's safe to stop taking mesalamine (a drug that helps control inflammation in the gut) for people with ulcerative colitis or Crohn's disease who are already on stronger treatments like biologics or immunomodulators. If you're doing well, this might reduce your daily pill burden.
This study looks at bacteria in your gut that may produce chemicals linked to ongoing pain in Crohn's disease or ulcerative colitis, even when the disease itself is not very active. Researchers want to understand why some people still have moderate to severe abdominal pain even after their inflammation has calmed down.
This study tests an investigational pill (PTT-621) for moderate to severe ulcerative colitis that hasn't responded well to standard treatments. It aims to see if the drug can reduce inflammation and improve symptoms, while checking safety and how the body handles it.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.